Cullinan Therapeutics Shares Preclinical Data for CLN-978
Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company, presented new preclinical data for CLN-978 at the American College of Rheumatology (ACR) Convergence 2025.
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases.
- Presented at ACR Convergence 2025 in Chicago, Illinois, October 24-29.
- Poster presentation session on October 28, 10:30 a.m.-12:30 p.m. CT (Poster Session C, Poster Number 2293).
- Cullinan Therapeutics also had a Booth (#1074) in the Exhibit Hall.
CLN-978, its novel investigational CD19xCD3 bispecific T cell engager.
Author's summary: Cullinan Therapeutics presents preclinical data for CLN-978.
More News
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- After Service Dog Helped her Journey to Recovery, Grad Student is Spreading the Word About Their Important Role
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Budget jitters see construction forecasts plummet
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Three resilient UK multinationals global managers are excited about | Trustnet
- Pressing need for ethical and regulatory oversight of therapeutic voice AI, SFU expert urges
- The environmental impact of the 2026 World Cup
- ICYMI: AAO 2025 showcases new technologies and continued research | Ophthalmology Times - Clinical Insights for Eye Specialists